DexCom also launched a share repurchase programme for up to $750m, concurrent with Q2 results. Credit: Around the World Photos / Shutterstock.

DexCom has released its second quarter (Q2) financials reporting a 15% growth in revenue to $1bn, up from $871.3m in Q2 2023.

However, it was the company’s annual revenue forecast that raised eyebrows among investors. It revised its full fiscal year guidance and now expects revenue of $4bn-$4.05bn, down from the $4.2bn-$4.35bn forecasted last quarter. The company’s stock was down by more than 38.7% in pre-market trading on 26 July, compared to the market close the day before.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

“While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards,” said Kevin Sayer, Dexcom’s chairman, president and CEO.

Despite reducing its year-end guidance, DexCom reported a 15.7% increase in operating income to $158m. The company experienced a 19% growth in US revenue and a 7% increase in international revenue.

DexCom also launched a share repurchase program for up to $750m, concurrent with Q2 results. The company also reported $3.12 in cash reserves.

DexCom competitor, Abbott, raised its full-year guidance last week. Abbott expects diluted earnings of $4.61 to $4.71 per share for the full fiscal year of 2024, compared to $4.55 to $4.70 diluted earnings per share forecasted last quarter.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The diabetes care market is expected to grow to be worth $33.5bn in 2030, as per the GlobalData market model. The glucose monitoring device segment is estimated  to grow to $6.7bn by 2033, with over-the-counter (OTC) continuous glucose monitors (CGMs) set to propel growth in this segment, as per GlobalData analysis.

In March 2024, the US Food and Drug Administration approved the first OTC CGM, Dexcom Stelo Glucose Biosensor System. The device is designed for individuals aged 18 and older who do not use insulin and provides continuous glucose measurements through a wearable sensor and  smartphone application.

DexCom’s highlights for the quarter include launching a direct-to-watch feature for the G7 CGM and new automated insulin delivery integrations, especially with Insulet. The company also secured reimbursement from the French Government for DexCom ONE CGM.